AIDDISON Explorer

AIDDISON Explorer is an advanced AI-powered drug discovery platform developed by Sigma-Aldrich, a part of Merck KGaA. This innovative tool is designed to significantly accelerate the early stages of drug development by integrating state-of-the-art artificial intelligence with computer-aided drug design (CADD) methodologies. It offers a comprehensive suite of functionalities that empower researchers to efficiently explore chemical space, identify promising drug candidates, and optimize their properties.

The platform leverages generative AI to facilitate de novo molecular generation, allowing scientists to create novel chemical structures with desired characteristics. Beyond generation, AIDDISON Explorer incorporates robust virtual screening capabilities, enabling rapid assessment of large compound libraries against specific biological targets. This helps prioritize compounds with the highest potential for efficacy and selectivity, reducing the need for extensive experimental testing.

Key features also include sophisticated ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) prediction models. These predictive analytics are crucial for early identification of potential issues related to drug pharmacokinetics and safety, thereby minimizing late-stage failures in the drug development pipeline. Furthermore, the platform assists with retrosynthesis planning, providing insights into the synthetic routes for newly designed molecules, which is vital for their practical realization in the lab.

For physicians and researchers involved in translational medicine or drug development, AIDDISON Explorer offers a powerful digital laboratory for hypothesis generation and validation. By streamlining the design and selection of drug candidates, it aims to bring novel therapies to patients faster and more cost-effectively, ultimately impacting patient care through advanced pharmaceutical innovation.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist